Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 5,325 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Continuous Dose Clear all

Conditions: Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
Interventions: Clazakizumab; Drug
Lead sponsor: Stanley Jordan, MD; Other
Eligibility: 15 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy
Interventions: Ixazomib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Failure, Chronic, Chronic Kidney Disease-Mineral and Bone Disorder
Interventions: Oral calcitriol with cinacalcet rescue, IV activated vitamin D; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: BAY2757556 (Larotrectinib, Vitrakvi); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more

Conditions: Melanoma Stage Iii, Melanoma Stage Iv, Melanoma, Melanoma (Skin), Cutaneous Melanoma
Interventions: Denosumab, Pembrolizumab, Nivolumab; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Manchester, New Hampshire • Chapel Hill, North Carolina

Conditions: Multiple Myeloma
Interventions: Busulfan; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 2
States / cities: Little Rock, Arkansas

Conditions: Cancer
Interventions: TAK-285 Dose Escalation Cohorts, TAK-285 Recommended Phase 2 Dosing Cohort; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Detroit, Michigan

Conditions: Light-Chain Amyloidosis
Interventions: Ixazomib, Dexamethasone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • Rochester, Minnesota + 2 more

Conditions: Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Interventions: Cemiplimab-Rwlc; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Delirium on Emergence
Interventions: Propofol, Sevoflurane, Isoflurane; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 2 Years to 12 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia
Interventions: AG-120, Nivolumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Functional Abdominal Pain, Functional Dyspepsia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
Interventions: Placebo Suspension, Hyoscyamine; Other · Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
Interventions: Thymus Tissue for Transplantation; Biological
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HCV
Interventions: Prophylaxis (P2W), Transmit and Treat (T&T); Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: La Jolla, California • Loma Linda, California • Baltimore, Maryland + 5 more

Conditions: Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions: zolbetuximab, nab-paclitaxel, gemcitabine; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 25
States / cities: Fullerton, California • Whittier, California • Meriden, Connecticut + 22 more

Conditions: Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
Interventions: Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 25 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Solid Tumor
Interventions: STP707; Drug
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more

Conditions: Non-small Cell Lung Cancer
Interventions: Carboplatin, Cetuximab; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 8
States / cities: Bentonville, Arkansas • Tucker, Georgia • Evanston, Illinois + 5 more

Conditions: Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
Interventions: Placebo SC, Placebo IV, Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 1,282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 77
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 74 more

Conditions: Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
Interventions: Tacrolimus, Methotrexate, Sirolimus; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years to 60 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 23
States / cities: Duarte, California • La Jolla, California • Stanford, California + 20 more

Conditions: HIV-1-Infection
Interventions: Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 35
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more

Conditions: Familial Chylomicronemia Syndrome
Interventions: Olezarsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Kansas City, Missouri + 3 more

Conditions: Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions: Cetuximab, EMD 1201081; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 4
States / cities: Aurora, Colorado • Lexington, Kentucky • Boston, Massachusetts + 1 more

Conditions: Metastatic Uveal Melanoma
Interventions: Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

DePTH: De-emphasize PTH

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients

A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Post Anesthesia Emergence and Behavioral Changes in Children Undergoing MRI

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Efficacy of Open Label Placebo in Children With FGIDs

Thymus Transplantation With Immunosuppression

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Tebentafusp-tebn With LDT in Metastatic UM